Novartis ASPIRES To Drive Use of Investigational Anti-Hypertensive Rasilez

Two outcomes intervention studies of aliskiren, which is currently pending at FDA, will begin in the first half of 2007.

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Archive

More from Pink Sheet